CN107456462A - Amino acid haemodialysis concentrate - Google Patents
Amino acid haemodialysis concentrate Download PDFInfo
- Publication number
- CN107456462A CN107456462A CN201610389468.3A CN201610389468A CN107456462A CN 107456462 A CN107456462 A CN 107456462A CN 201610389468 A CN201610389468 A CN 201610389468A CN 107456462 A CN107456462 A CN 107456462A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- dialysis solution
- blood dialysis
- haemodialysis
- proline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
Abstract
The present invention provides a kind of amino acid haemodialysis concentrate, by weight, including arginine 5~50, histidine 5~50, isoleucine 5~50, lysine hydrochloride 5~50, methionine 5~50, phenylalanine 5~50, threonine 5~50, tryptophan 2~40 and valine 5~60, in addition to leucine 20~50, alanine 5~28, glycine 5~28, tyrosine 35~40, serine 5~10 and proline 28~50.The present invention also provides a kind of amino acid blood dialysis solution and preparation method thereof.Blood dialysis solution of the present invention can effectively reduce the generation of hypertension in blood dialysis, and vascular smooth muscle is loose, vasodilation, reduce the incidence of hypertension.
Description
Technical field
A kind of amino acid haemodialysis concentrate of the present invention.The present invention relates to a kind of haemodialysis compound amino acidemia
Liquid dialysate concentrate, for patients of chronic renal failure, especially suitable for underfed hemodialysis patients, with blood
The haemodialysis preparation and its process of preparing of the form supplement amino acid nutrient of hemodialysis liquid.
Background technology
During chronic renal insufficiency, need limit protein to take in, endocrine dysfunction and Aminoacidopathy occurs.Blood
Liquid dialysis is important means that patients of chronic renal failure is survived, can remove toxin, correct salt metabolism it is disorderly and
Acid-base imbalance, but long-term haemodialysis can aggravate the disorder of amino acid metabolism, and there are some researches prove each haemodialysis is lost
Amino acid, peptides about 10~13g, the necessary amino acid starvation of patient's body amino acid especially essential amino acid and condition, lead
Cause vivo protein synthesis reduce, body protein decompose accelerate, malnutrition, so as to cause the nutrition of patient not
It is good.The malnutrition of hemodialysis patients is its complication and the important determinant of death, therefore before dialysis sufficiently
Put, it is unbalance how to correct the amino acid metabolism of Maintenance Hemodialysis Patients, and improving its malnutrition is and its important
Problem.
The content of the invention
It is an object of the invention to provide a kind of amino acid haemodialysis concentrate,.
The technical scheme is that：
Amino acid haemodialysis concentrate, by weight, including it is arginine 5~50, histidine 5~50, different
Leucine 5~50, lysine hydrochloride 5~50, methionine 5~50, phenylalanine 5~50, threonine 5~50, color
Propylhomoserin 2~40 and valine 5~60, also include in the amino acid haemodialysis concentrate leucine 20~50,
Alanine 5~28, glycine 5~28, tyrosine 35~40, serine 5~10 and proline 28~50.
The amino acid haemodialysis concentrate of the present invention can effectively reduce the generation of hypertension in blood dialysis.
Hypertension is CKD (CKD) patient and the most common complication of MHD (MHD) patient, is to influence MHD
The long-term hypertension of patient, and with the progress of kidney trouble, the incidence more and more higher of hypertension, with glomerular filtration rate(GFR
(GFR) decline is almost linear.Independent factor through survival rate, it is closely related with the quality of life of dialysis patient.
The present invention is it was discovered by researchers that contain leucine 20~50, alanine 5~28, sweet ammonia in haemodialysis concentrate
Acid 5~28, tyrosine 35~40, serine 5~10 and proline 28~50, sent out in the blood of haemodialysis and patient
Raw ion exchange, into human body after turn into the precursors of internal various neurotransmitters, supplemented with exogenous acidic amino acid can influence this
The synthesis and release of a little neurotransmitters, so as to have adjusted the blood pressure of body, and act on it is extensive, while can also disturb calcium with it is low
The combination in affinity site, reduces Ca2+ influx, and vascular smooth muscle is loose, vasodilation, reduces the incidence of hypertension.
Described amino acid haemodialysis concentrate, by weight, the amino acid haemodialysis concentrate
Include leucine 30~50, alanine 10~25, glycine 10~25, tyrosine 35~40, serine 5~10
With proline 3 5~45.
A kind of amino acid blood dialysis solution, the amino acid blood dialysis solution are saturating by the amino acid blood
Analysis concentrate dilution forms, in the amino acid blood dialysis solution containing 5~50mg/L of arginine, histidine 5~
50mg/L, 5~50mg/L of isoleucine, 5~50mg/L of lysine hydrochloride, 5~50mg/L of methionine, phenylalanine
5~50mg/L, 5~50mg/L of threonine, 2~40mg/L of tryptophan, 5~60mg/L of valine, 20~50mg/L of leucine,
5~28mg/L of alanine, 5~28mg/L of glycine, 35~40mg/L of tyrosine, 5~10mg/L of serine, proline
28~50mg/L.
Contain 5~50mg/L of arginine, 5~50mg/L of histidine, different bright ammonia in the amino acid blood dialysis solution
5~50mg/L of acid, 5~50mg/L of lysine hydrochloride, 5~50mg/L of methionine, 5~50mg/L of phenylalanine, Soviet Union
5~50mg/L of propylhomoserin, 2~40mg/L of tryptophan, 5~60mg/L of valine, 30~50mg/L of leucine, alanine
10~25mg/L, 10~25mg/L of glycine, 35~40mg/L of tyrosine, 5~10mg/L of serine and proline 3 5~
45mg/L
In the amino acid blood dialysis solution also containing 135~140mmol/L of sodium ion, calcium ion 1.25~
1.75mmol/, 0.25~1.0mmol/L of magnesium ion, 0~4.0mmol/L of potassium ion, 100~115mmol/L of chlorion,
0~5mmol/L of 28~38mmol/L of bicarbonate ion, 0~4g/L of glucose and pH adjusting agent.
In the amino acid blood dialysis solution containing 0~3.5mmol/L of potassium ion, 105~112mmol/L of chlorion,
29~36mmol/L of bicarbonate ion, 0.5~3g/L of glucose, 1~4.5mmol/L of pH adjusting agent.
A kind of preparation method of described amino acid blood dialysis solution, comprises the following steps：
1) amino acid, electrolyte, pH adjusting agent and glucose are added in deionized water and dissolved, filled under nitrogen protection
Dress sealing, sterilizes, and packaging, obtains A liquid；
2) mixture of single sodium acid carbonate or sodium acid carbonate and sodium chloride is added in deionized water and dissolved, it is filling
Sealing, obtain B liquid；
3) during clinical practice, A liquid, B liquid and deionized water are mixed, obtain amino acid blood dialysis solution.
Amino acid haemodialysis concentrate provided by the invention has advantages below
1st, amino acid haemodialysis concentrate of the invention, can effectively reduce the blood plasma of patient over the course for the treatment of
The loss of free amino acid, adjust patient's body amino acid content.Both hemodialysis patients can have been solved because many factors cause
The problem of being orally ingested albumen deficiency, it turn avoid otherwise extra-nutrition (such as nasal feeding, venoclysis) and drawn
The additional injuries risen.Required epoxide acid/nonessential amino acid normal ratio can be recovered, make the urea-N transformation in retention body be
Nonessential amino acid, you can promote positive nitrogen equilibrium, blood urea nitrogen can be reduced again, so as to improve renal function.In addition during renal failure
After supplementing essential amino acid, serum paraoxonase can be promoted to enter intracellular, so as to reduce serium inorganic phosphorus, improve symptom, improve patient's life
Deposit quality.
2nd, amino acid haemodialysis concentrate of the invention is sterile preparation, and traditional haemodialysis concentrate goes out to be non-
Bacteria preparation, wherein containing substantial amounts of microorganism, the growth and breeding of microorganism can produce substantial amounts of endotoxin, saturating by blood
Analysis can produce endotoxemia after entering human body, and endotoxemia can cause human body to generate heat, leukocyte count change, bleeding
Tendency, heart failure, renal hypofunction, hepar damnification, neurological symptom, and shock etc., can cause when serious
MOF, disseminated intravascular coagulation etc., even result in death.The amino acid blood of the present invention
Dialysate concentrate can all kill the microorganism in amino acid haemodialysis concentrate after high-temperature sterilization, avoid
Because the growth and breeding of microorganism and influence of the caused endotoxin to patient.
3rd, amino acid haemodialysis concentrate of the invention can effectively reduce the hair of hypertension in blood dialysis
It is raw.Hypertension is CKD (CKD) patient and the most common complication of MHD (MHD) patient, is shadow
The long-term hypertension of MHD patient is rung, and with the progress of kidney trouble, the incidence more and more higher of hypertension, with glomerulus
The decline of filtration rate (GFR) is almost linear.Independent factor through survival rate, it is close with the quality of life of dialysis patient
It is related.
Embodiment
Embodiment 1
Amino acid haemodialysis concentrates medicinal powder
Take 0.175~0.98g of alanine, arginine 0.175g~1.75g, glycine 0.175g~0.98g,
Histidine 0.175g~1.75g, isoleucine 0.175g~1.75g, leucine 0.175g~1.75g,
Lysine hydrochloride 0.175g~1.75g, methionine 0.175g~1.75g, phenylalanine 0.175g~1.75g,
Proline 0.175g~1.75g, serine 0.175g~1.75g, threonine 0.175g~1.75g,
Tryptophan 0.07g~1.4g, 0.035~1.4g of tyrosine, valine 0.175g~2.1g,
Sodium chloride 204.5-235, calcium chloride 6.02g~8.42g, magnesium chloride 1.78g~7.12g, potassium chloride 2.61g~10.44g,
0~140g/L of glucose, glacial acetic acid, citric acid, lactic acid, 0~1.5-33.6g of malic acid.
Embodiment 2
Amino acid haemodialysis concentrates medicinal powder
A agent：Weigh take alanine 0.175g, arginine 0.175g, glycine 0.175g~0.98g,
Histidine 1.75g, isoleucine 1.75g, leucine 1.75g,
Lysine hydrochloride 1.0g, methionine 0.5g, phenylalanine 0.5g,
Proline 1.0g, serine 0.4g, threonine 1.25g,
Tryptophan 1.1g, tyrosine 0.2g, valine 1.6g,
Sodium chloride 204.5g, calcium chloride 6.5g, magnesium chloride 2.5g, potassium chloride 3.3g, glacial acetic acid 8.4g
B agent：Sodium acid carbonate 84g is taken, is packed
Embodiment 3
Amino acid haemodialysis concentrates medicinal powder
A agent：Take alanine 0.2g, arginine 0.5g, glycine 0.45g,
Histidine 0.175g, isoleucine 0.175g, leucine 0.175g,
Lysine hydrochloride 1.75g, methionine 1.75g, phenylalanine 1.75g,
Proline 0.8g, serine 1.5g, threonine 0.9g,
Tryptophan 0.14g, tyrosine 0.7g, valine 1.3g,
Sodium chloride 210, calcium chloride 6.02g, magnesium chloride 3.56g, potassium chloride 5.0g, glucose 35g, citric acid 8g mixing
After uniformly, packaging
B agent：Sodium acid carbonate 70g
Embodiment 4
Amino acid haemodialysis concentrates medicinal powder
Take alanine 0.25g, arginine 0.8g, glycine 0.4g,
Histidine 1.3g, isoleucine 0.7g, leucine 1.25g,
Lysine hydrochloride 0.175g, methionine 0.175g, phenylalanine 0.175g,
Proline 1.75g, serine 1.75g, threonine 1.75g,
Tryptophan 0.1g, tyrosine 0.5g, valine 1.2g,
Sodium chloride 160g, calcium chloride 7.22g, magnesium chloride 5.0g, potassium chloride 8.4g, glucose 140g, lactic acid 3.0g, mix
After closing uniformly, packaging
B agent：Sodium acid carbonate 66g, sodium chloride 30g are taken, is packed
Embodiment 5
Amino acid haemodialysis concentrates medicinal powder
Take alanine 0.45g, arginine 0.85g, glycine 0.7g,
Histidine 1.35g, isoleucine 0.55g, leucine 0.8g,
Lysine hydrochloride 0.65g, methionine 1.5g, phenylalanine 1.5g,
Proline 0.175g, serine 0.175g, threonine 0.175g,
Tryptophan 1.4g, tyrosine 1.4g, valine 2.1g,
Sodium chloride 210g, calcium chloride 6.2g, magnesium chloride 7.12g, potassium chloride 2.61gg, lactic acid, malic acid 50g are well mixed
Afterwards, pack
B agent：Sodium acid carbonate 82g is taken, after being dissolved with purified water, is sealed, packaging.
Embodiment 6
Amino acid haemodialysis concentrates medicinal powder
Take alanine 0.8g, arginine 1.24g, glycine 0.5g,
Histidine 1.5g, isoleucine 0.4g, leucine 0.75g,
Lysine hydrochloride 1.5g, methionine 1.0g, phenylalanine 1.0g,
Proline 0.8g, serine 1.6g, threonine 0.2g,
Tryptophan 0.07g, tyrosine 0.035g, valine 0.175g,
Sodium chloride 216, calcium chloride 6.02gg, magnesium chloride 3.56g, potassium chloride 2.61gg, glucose 35g, glacial acetic acid 8.4g
After well mixed, packaging
B agent：After taking sodium acid carbonate 78g to be dissolved with purified water, seal, packaging.
Embodiment 7
Amino acid haemodialysis concentrates medicinal powder
Take alanine 0.98g, arginine 1.75g, glycine 0.98g,
Histidine 0.2g, isoleucine 1.1g, leucine 1.0g,
Lysine hydrochloride 0.3g, methionine 0.4g, phenylalanine 1.6g,
Proline 1.2g, serine 1.0g, threonine 1.5g,
Tryptophan 0.1g, tyrosine 0.1g, valine 2.0g,
Sodium chloride 220g, calcium chloride 7.5g, magnesium chloride 4.0g, potassium chloride 5.0g, citric acid 10g.
B agent：Sodium acid carbonate 75g is taken to pack.
Embodiment 8
Amino acid haemodialysis concentrate liquid
Take alanine 1.0g, arginine 1.0g, glycine 0.5g,
Histidine 1.2g, isoleucine 0.4g, leucine 0.6g,
Lysine hydrochloride 0.8g, methionine 1.25g, phenylalanine 0.5g,
Proline 0.6g, serine 0.56g, threonine 0.74g,
Tryptophan 1.0g, tyrosine 1.1g, valine 1.8g,
Sodium chloride 210g, calcium chloride 6.84g, magnesium chloride 4.5g, potassium chloride 6.2, glucose 80g, glacial acetic acid 10g dissolvings
Into appropriate water for dialysis, filling and sealing, sterilizes under nitrogen protection, packaging.Sterilising conditions：115℃30min
B agent：Sodium acid carbonate 85g is taken to pack.
Embodiment 9
Amino acid haemodialysis concentrate liquid
Take alanine 0.5g, arginine 0.5g, glycine 0.5g,
Histidine 1.0g, isoleucine 1.0g, leucine 0.6g,
Lysine hydrochloride 0.35, methionine 0.85g, phenylalanine 0.36g,
Proline 1.6g, serine 0.32g, threonine 0.75g,
Tryptophan 1.2g, tyrosine 0.56g, valine 0.87g,
Sodium chloride 230g, calcium chloride 7.4g, magnesium chloride 5.0g, potassium chloride 6.0g, citric acid 28g are dissolved to appropriate, pure
Change in water or injection, under nitrogen protection filling and sealing, sterilize, packaging.Sterilising conditions：121℃15min.
B agent：Sodium acid carbonate 94g is taken to pack.
Embodiment 10
Amino acid haemodialysis concentrate liquid
Take alanine 0.6g, arginine 0.8g, glycine 0.7g,
Histidine 1.2g, isoleucine 0.4g, leucine 0.6g,
Lysine hydrochloride 0.35, methionine 0.85g, phenylalanine 0.36g,
Proline 1.1g, serine 0.42g, threonine 0.95g,
Tryptophan 1.1g, tyrosine 0.5g, valine 0.6g,
Sodium chloride 160g, calcium chloride 7.2g, magnesium chloride 4.0g, potassium chloride 5.2g, citric acid 18g are dissolved to appropriate injection
With in water, filling and sealing, sterilizes under nitrogen protection, packaging.Sterilising conditions：121℃8min.
B agent：Sodium acid carbonate 66g, sodium chloride 30g are taken, after being dissolved with appropriate purified water, is sealed, packaging.
Embodiment 11
Amino acid haemodialysis concentrate liquid
Take alanine 0.4g, arginine 1.0g, glycine 0.5g,
Histidine 1.1g, isoleucine 1.2g, leucine 0.7g,
Lysine hydrochloride 0.55, methionine 0.65g, phenylalanine 0.45g,
Proline 1.2g, serine 0.62g, threonine 0.8g,
Tryptophan 1.3g, tyrosine 0.56g, valine 0.87g,
Sodium chloride 230g, calcium chloride 7.2g, magnesium chloride 3.56g, potassium chloride 5.22g, glacial acetic acid 8.4g are dissolved to appropriate saturating
In analysis water, filling and sealing, sterilizes under nitrogen protection, packaging.Sterilising conditions：115℃30min.
B agent：After taking sodium acid carbonate 84g to be dissolved with appropriate purified water, seal, packaging.
Embodiment 12
Amino acid haemodialysis concentrate liquid
Take alanine 1.0g, arginine 1.0g, glycine 0.5g,
Histidine 0.5g, isoleucine 0.4g, leucine 0.6g,
Lysine hydrochloride 0.8g, methionine 1.25g, phenylalanine 0.5g,
Proline 0.6g, serine 0.8g, threonine 0.74g,
Tryptophan 1.0g, tyrosine 1.1g, valine 1.5g,
Sodium chloride 210g, calcium chloride 7.7g, magnesium chloride 3.6g, potassium chloride 5.2, glucose 35g, glacial acetic acid 8.4g dissolvings
Into appropriate water for dialysis, filling and sealing, sterilizes under nitrogen protection, packaging.Sterilising conditions：121℃8min.
B agent：Sodium acid carbonate 84g is taken to pack.
Embodiment 13
Amino acid haemodialysis concentrate liquid
Take alanine 0.8g, arginine 1.0g, glycine 0.98g,
Histidine 0.2g, isoleucine 1.0g, leucine 1.0g,
Lysine hydrochloride 0.3g, methionine 0.4g, phenylalanine 1.6g,
Proline 1.2g, serine 1.0g, threonine 1.2g,
Tryptophan 0.1g, tyrosine 0.1g, valine 2.0g,
Sodium chloride 220g, calcium chloride 7.5g, magnesium chloride 4.0g, potassium chloride 5.0g, citric acid 10g are dissolved to appropriate dialysis
With in water, filling and sealing, sterilizes under nitrogen protection, packaging.Sterilising conditions：115℃30min.
B agent：After taking sodium acid carbonate 84g to be dissolved with appropriate purified water, seal, packaging.
Experimental example：Patients' blood's situation of change in blood dialysis
120 normotensive dialysis patients are randomly divided into experimental group and control group, every group of 60 people, observe patients with hemodialysis
During blood pressure situation.
Under hypertension index definition blood pressure choosing method patient's quiet environment, dorsal position rest 5-10min, with electronic sphygmomanometer
Blood pressure before dialysing is surveyed at 3cm on the upper limbs elbow of non-piercing side, randomly selects the data of continuous one month, record each group occurs
The number of hypertension.
Experimental group：The product made using embodiment 10
Control group：Using the commercially available haemodialysis concentrate without amino acid
Experimental result：
| Experimental group | Control group | |
| Number | 2 | 7 |
| Percentage (%) | 3.3 | 11.7 |
Result of the test shows that the incidence that the present invention provides embodiment hypertension in blood dialysis is 3.3%, and is adopted
The ratio for occurring hypertension with the patient of conventional hemodialysis concentrate is up to 11.7%, and invention provides embodiment product and controlled
What hypertension occurred in dialysis patient is substantially better than commercially available prod.
Embodiments of the invention are described in detail above, but the content is only presently preferred embodiments of the present invention, no
The practical range for limiting the present invention can be considered as.Any changes and modifications in accordance with the scope of the present application,
All should still it belong within the patent covering scope of the present invention.
Claims (7)
1. amino acid haemodialysis concentrate, by weight, including arginine 5~50, histidine 5~50, isoleucine 5~50, lysine hydrochloride 5~50, methionine 5~50, phenylalanine 5~50, threonine 5~50, tryptophan 2~40 and valine 5~60, it is characterised in that：Also include leucine 20~50, alanine 5~28, glycine 5~28, tyrosine 35~40, serine 5~10 and proline 28~50 in the amino acid haemodialysis concentrate.
2. amino acid haemodialysis concentrate according to claim 1, it is characterised in that：By weight, the amino acid haemodialysis concentrate includes leucine 30~50, alanine 10~25, glycine 10~25, tyrosine 35~40, serine 5~10 and proline 3 5~45.
A kind of 3. amino acid blood dialysis solution, it is characterised in that：The amino acid blood dialysis solution is formed by amino acid haemodialysis concentrate dilution, contain 5~50mg/L of arginine in the amino acid blood dialysis solution, 5~50mg/L of histidine, 5~50mg/L of isoleucine, 5~50mg/L of lysine hydrochloride, 5~50mg/L of methionine, 5~50mg/L of phenylalanine, 5~50mg/L of threonine, 2~40mg/L of tryptophan, 5~60mg/L of valine, 20~50mg/L of leucine, 5~28mg/L of alanine, 5~28mg/L of glycine, 35~40mg/L of tyrosine, 5~10mg/L of serine, 28~50mg/L of proline.
4. amino acid blood dialysis solution according to claim 3,5~50mg/L of arginine, 5~50mg/L of histidine, 5~50mg/L of isoleucine, 5~50mg/L of lysine hydrochloride, 5~50mg/L of methionine, 5~50mg/L of phenylalanine, 5~50mg/L of threonine, 2~40mg/L of tryptophan, 5~60mg/L of valine, 30~50mg/L of leucine, 10~25mg/L of alanine, 10~25mg/L of glycine, 5~45mg/L of 35~40mg/L of tyrosine, 5~10mg/L of serine and proline 3 are contained in the amino acid blood dialysis solution.
5. amino acid blood dialysis solution according to claim 4, it is characterised in that：Also containing 135~140mmol/L of sodium ion, 1.25~1.75mmol/ of calcium ion, 0.25~1.0mmol/L of magnesium ion, 0~4.0mmol/L of potassium ion, 100~115mmol/L of chlorion, 28~38mmol/L of bicarbonate ion, 0~5mmol/L of 0~4g/L of glucose and pH adjusting agent in the amino acid blood dialysis solution.
6. amino acid blood dialysis solution according to claim 5, it is characterised in that：Contain 0~3.5mmol/L of potassium ion, 105~112mmol/L of chlorion, 29~36mmol/L of bicarbonate ion, 0.5~3g/L of glucose, 1~4.5mmol/L of pH adjusting agent in the amino acid blood dialysis solution.
A kind of 7. preparation method of the amino acid blood dialysis solution described in claim 3-6 any one, it is characterised in that：Comprise the following steps：
1) amino acid, electrolyte, pH adjusting agent and glucose are added in deionized water and dissolved, under nitrogen protection filling and sealing, sterilized, packaging, obtain A liquid；
2) mixture of single sodium acid carbonate or sodium acid carbonate and sodium chloride is added in deionized water and dissolved, filling and sealing, obtain B liquid；
3) during clinical practice, A liquid, B liquid and deionized water are mixed, obtain amino acid blood dialysis solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610389468.3A CN107456462A (en) | 2016-06-02 | 2016-06-02 | Amino acid haemodialysis concentrate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610389468.3A CN107456462A (en) | 2016-06-02 | 2016-06-02 | Amino acid haemodialysis concentrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107456462A true CN107456462A (en) | 2017-12-12 |
Family
ID=60545518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610389468.3A Pending CN107456462A (en) | 2016-06-02 | 2016-06-02 | Amino acid haemodialysis concentrate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107456462A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102370640A (en) * | 2010-08-18 | 2012-03-14 | 俞黎黎 | Compound amino acid preparation for hemodialysis and hemodialysis preparation containing same |
-
2016
- 2016-06-02 CN CN201610389468.3A patent/CN107456462A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102370640A (en) * | 2010-08-18 | 2012-03-14 | 俞黎黎 | Compound amino acid preparation for hemodialysis and hemodialysis preparation containing same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9861575B2 (en) | Vitamin-containing nutrition infusion for administration through peripheral vein | |
| KR102057555B1 (en) | Carboxylic Acid Mixtures to Treat Patients with Renal Failure | |
| US6689393B1 (en) | Solution, in particular for hemodialysis or peritoneal dialysis and a method of preparing same | |
| CN106659711A (en) | Durable preparation of an injectable of melatonin exhibiting long-term stability | |
| CN105380936A (en) | Iron metabolism-improving agent | |
| CN100486579C (en) | Transfusion preparation for peripheral intravenous administration and method of stabilizing vitamin b1 | |
| CN108066360A (en) | A kind of compound sodium acetate ringer's injection and preparation method thereof | |
| WO1992009277A1 (en) | Nutrient supply | |
| JPH01301619A (en) | Amino acid pharmaceutical for cancer | |
| JPH0116809B2 (en) | ||
| JP2007056013A (en) | Supplementary liquid for dialysis | |
| ES2790948T3 (en) | Dialysis solution comprising creatine for cell protection | |
| CN107456462A (en) | Amino acid haemodialysis concentrate | |
| CA1334575C (en) | Substitution fluid preparation comprising 3-hydroxybutyric acid (beta-hydroxybutyric acid) and its salts | |
| WO2000043035A1 (en) | Amino acid-containing albumin preparations | |
| EP0416108B1 (en) | Nutritious composition | |
| US20050100615A1 (en) | Process for controlling water and electrolyte balance and acid-base equilibrium in human body | |
| CN106309481A (en) | Compound potassium aspartate-glucose injection and preparation method thereof | |
| CN107854426A (en) | A kind of novel amino peritoneal dialysis solution | |
| JPH09110686A (en) | Macrophage nitrogen monoxide-producing sthenic agent | |
| CN106491601A (en) | A kind of Amino Acid Compound Injection and preparation method thereof | |
| JP4622311B2 (en) | Peripheral intravenous infusion | |
| JP5271480B2 (en) | Body temperature reduction inhibitor | |
| RU2721605C1 (en) | Pharmaceutical composition for parenteral drop introduction | |
| RU2709501C1 (en) | Pharmaceutical composition for parenteral drip introduction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171212 |
|
| RJ01 | Rejection of invention patent application after publication |